Break­ing: Pfiz­er in hot pur­suit of a $5B buy­out of Glob­al Blood Ther­a­peu­tics — re­port

Pfiz­er CEO Al­bert Bourla has vowed to leave no stone un­turned in the search for new biotech deals, and the BD team is not let­ting him down.

The Wall Street Jour­nal re­port­ed to­day that Pfiz­er is in the fi­nal stages of ac­quir­ing Glob­al Blood Ther­a­peu­tics for $5 bil­lion. Ac­cord­ing to the Jour­nal re­port, though, Pfiz­er is not the on­ly buy­er at the deal ta­ble and while the phar­ma gi­ant may be close to clinch­ing it, there are no guar­an­tees it will con­tin­ue.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER